Podcasts about Ovarian cancer

‘Liminal' is much more than the name of award-winning author, journalist and Ovarian cancer wrangler Jennifer Steil's Substack newsletter. In this extended episode, the winner of the Grand Prize in the international Eyelands 2020 Book Awards and Finalist for the 2021 Lambda Literary Lesbian Fiction Award for Exile Music,talks about the kidnap experience and resulting ‘what if's that inspired her first novel, The Ambassador's Wife,and how writing has become even more important to mental health during her cancer treatment. Liminal spaces she discusses with Dr Rachel Knightley include ‘home', and how that truly means wherever her husband and daughter are – whatever country or even hospital room that is today.   Discover more about Jennifer by subscribing to Liminal: https://jennifersteil.substack.com   Sponsor this year's Green Ink Sponsored Write for Macmillan Cancer Support: https://www.justgiving.com/page/somewhere-thats-green   Visit the Writers' Gym: https://www.writersgym.com/

聊中西文化，也聊很多东西！ 第七十六期，大家每年去体检吗？从安吉丽娜朱莉切掉乳腺和卵巢开始聊起，谈一谈对癌症预防的小小想法。 00:37 安吉丽娜·朱莉因于2013和2015年分别切除乳腺与卵巢 03:38 不同国家的体检差异 07:00 2022年WTO癌症数据 12:00 呼吁关注健康 欢迎给我们来信： ttmiChinese@gmail.com Have online class with Candice, please email candicex2018@gmail.com YouTube: Candice X Chinese Mandarin Instagram: CandiceXMandarin2022 免费学习资料 Free study materials please visit Patreon: https://www.patreon.com/candicex PDF full script for episode 76: https://www.patreon.com/posts/133444274 Full subtitles with Pinyin for episode 76: https://youtu.be/RDudz2IXYAQ

  **Gal

Hollywood actor Tim Pocock was tricked by his dying, devout mother into undergoing gay conversion therapy. After she died, Tim finally learned how to be himself, without fear and self-loathing.Tim grew up under the thumb of his charismatic, pious mother.He went to a school with links to the controversial, secretive and conservative Catholic organisation, Opus Dei.There, he desperately tried to hide his sexuality, and was ruthlessly bullied for his musical and stage talents.Despite Tim's success in Australian opera, television, and in Hollywood blockbusters, he continued to harbour many secrets about himself and his family.One day his mother, who loved Tim deeply in her own way, and who was dying from ovarian cancer, convinced her only son to come with her to therapy. Instead of finally being able to talk about his struggles, Tim found himself being tricked into gay conversion therapy.For the last few months of his mother's life, he went to be hypnotised by a 'Catholic psychologist' every week, until eventually she died, and Tim was set free to learn how live by and for himself.Further informationThe Truth Will Set You Free: Growing up gay in Opus Dei is published by Hachette.You can stream the Four Corners report into schools with ties to Opus Dei, which features Tim, on ABC iview.The Pared Foundation's full responses to questions from Four Corners can be read here.Opus Dei Australia provided Four Corners with this statement.Find out more about the Conversations Live National Tour on the ABC website.This episode of Conversations was produced by Meggie Morris and presented by Richard Fidler. The executive producer is Nicola Harrison.This episode explores sexuality, LGBTQI+, homophobia, family dynamics, books, writing, mother-son relationships, shame, the Church, infidelity, cancer, death, grief, losing a mother, acting, a career in acting, memoir, epic life story, origin story, Marvel, Wolverine, Cyclopse, Dance Academy, Tangara, Redfield.

Normally a diagnosis of Ovarian Cancer happens to women who are much older than 14 years old, which is what happened to Olivia Hebert in October of 2024. Olivia has been through some difficult times since her diagnosis including a temporary loss of her vision, but she was able to return to school in March, her vision has been getting better, and she is just finishing up a vacation to Disneyworld with her family. 

Ovarian Cancer Awareness Month isn't until September, but on June 28th Gilda Radner would've turned 79. Gilda's Clubs nationwide are using the date to bring national attention to a disease that affects over 19,000 women every year in our country. Kristian White, Vice President of Gilda's Club South Florida.The saying is ‘It's a Man's World' - but glass ceilings have been being shattered for generations, by groundbreaking women. Kelly Ramsey - author of: Wildfire Days: A Woman, a Hotshot Crew, and the Burning American West.

Ovarian Cancer Awareness Month isn't until September, but on June 28th Gilda Radner would've turned 79. Gilda's Clubs nationwide are using the date to bring national attention to a disease that affects over 19,000 women every year in our country. Kristian White, Vice President of Gilda's Club South Florida.The saying is ‘It's a Man's World' - but glass ceilings have been being shattered for generations, by groundbreaking women. Kelly Ramsey - author of: Wildfire Days: A Woman, a Hotshot Crew, and the Burning American West.

Cypriot scientists make a breakthrough in identifying genetic markers that could lead to breast and ovarian cancers; despite the Middle East ceasefire we may still see an impact on oil prices, and in Cyprus that usually means an increase in our electricity bills. 

Ovarian Cancer Awareness Month isn't until September, but on June 28th Gild Radner would've turned 79. Gilda's Clubs nationwide are using the date to bring national attention to a disease that affects over 19,000 women every year in our country. Kristian White, Vice President of Gilda's Club South Florida. The saying is ‘It's a Man's World' - but glass ceilings have been being shattered for generations, by groundbreaking women. Kelly Ramsey - author of: Wildfire Days: A Woman, a Hotshot Crew, and the Burning American West.

Ovarian Cancer Awareness Month isn't until September, but on June 28th Gild Radner would've turned 79. Gilda's Clubs nationwide are using the date to bring national attention to a disease that affects over 19,000 women every year in our country. Kristian White, Vice President of Gilda's Club South Florida. The saying is ‘It's a Man's World' - but glass ceilings have been being shattered for generations, by groundbreaking women. Kelly Ramsey - author of: Wildfire Days: A Woman, a Hotshot Crew, and the Burning American West.

Dr David O'Malley and Dr Shannon Westin summarize the clinical treatment landscape for ovarian cancers, supported by clinical perspectives and management strategies from nurse practitioners Ms Courtney Arn and Ms Jennifer Filipi. NCPD information and select publications here.

Onsite at ASCO 2025 in Chicago, web editor Nicole Raleigh sat down with Dr Stacy Lindborg, CEO of IMUNON, to discuss the company's oral presentation at the Congress from the Phase 2 OVATION 2 study of IMNN-001, an IL-12 immunotherapy, in women with newly diagnosed advanced ovarian cancer – since published in the peer-reviewed journal Gynecologic Oncology today. Dr Lindborg shares her journey to her present role, the true potential shown in this new data for addressing unmet needs in advanced ovarian cancer, and the oncological space – and ASCO 2025 itself – more generally. You can also listen to episode 185a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

This week's episode will be focusing on Ovarian Cancer with 2025 updates since we last covered this topic in 2022. We will go over all important details on the risk factors, presentation, diagnosis, staging & treatment options for both localized and metastatic disease. 

Dr Bill Nelson talks with Dr Denis Wirtz about his research using CODA, an artificial intelligence platform, to identify and analyze pre-cancerous lesions previously undetected in the pancreas and along the fallopian tubes.

Jennifer Vertentes was a police officer in Providence Rhode Island when she decided to go to Hasbro Children's Hospital on Thanksgiving Day of 2018 to meet kids who had to spend their Thanksgiving being treated for different reasons, including being treated for Pediatric Cancer. While she was there she met 3 year old Emerson Lucier who was going through her 3rd battle with Acute Myeloid Leukemia . This meeting inspired Jennifer to start her HERO PACKAGE FOUNDATION to help put a smile on the faces of these kids who were battling these difficult diseases. Jennifer, who in 2023 had to retire from the Police Department after suffering an injury while trying to save a person who was drowning, was also diagnosed with Ovarian Cancer that year. Fortunately for the Pediatric Cancer community, she continues to help these kids as she deals with her disease, that fortunately was diagnosed at a very early stage. 

Get the same amazing support that Ana received!  Apply to join the Cancer Freedom Program Click HERE: www.cancerfreedomprogram.com ‘When I walked out of chemo I was totally terrified.  Was this it?” That's a quote from stage 3 ovarian cancer survivor, Ana Arias.  After being diagnosed at the age of 35, Ana knew that chemotherapy and surgery were going to be difficult but manageable.  As she went through chemo, she began to feel secure in having an ongoing defence against cancer. But when those chemo cycles came to an end - the uncertainty and fear started creeping in.  In this episode of the Cancer Freedom Podcast, Ana, shares how she navigated her cancer recovery and what allowed her to be on a path to being the healthiest she has ever been.   PS - Whenever you are ready, here the 2 best ways I can help you -  1) “Your A-Z Guide to Staying Cancer Free” **FREE** Click here: https://dramycancer.com/azcancerfree 2)Join the Cancer Freedom Program  Click HERE: www.cancerfreedomprogram.com   ***Let's Connect: Website: www.cancerfreedomprogram.com YouTube: https://www.youtube.com/channel/UCUt9...  

BUFFALO, NY - June 3, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on May 19, 2025, titled “PRDX1 protects ATM from arsenite-induced proteotoxicity and maintains its stability during DNA damage signaling." In this study, led by first author Reem Ali and corresponding author Dindial Ramotar from Hamad Bin Khalifa University in Qatar, researchers discovered that a protein called PRDX1 helps maintain the stability of ATM, a key protein involved in repairing damaged DNA, especially when cells are under stress from arsenite exposure. The study found that without PRDX1, cells lose their ability to repair DNA and become more sensitive to chemotherapy. This finding suggests that targeting PRDX1 could improve the success of some cancer treatments. PRDX1 is already known for its role in protecting cells from oxidative damage, but this study shows it also plays a role in the DNA repair process. ATM is an essential protein that detects breaks in DNA and starts the repair process. When PRDX1 is missing, ATM is rapidly lost, especially when cells are exposed to arsenite, a toxic substance found in the environment. Without ATM, the DNA repair system fails, leaving cells more vulnerable to damage. By using both human cell lines and clinical samples from ovarian cancer patients, the team showed that high levels of PRDX1, along with ATM and MRE11 (another DNA repair protein), were linked to tumors' aggressive features and lower patient survival rates. This pattern suggests that tumors with high PRDX1 may resist chemotherapy by increasing their DNA repair capacity. On the other hand, removing PRDX1 weakened the repair system and made cancer cells more responsive to DNA-damaging platinum drugs. The study also showed that combining low doses of arsenite with drugs that either block ATM or damage DNA caused a much higher rate of cancer cell death in cells that lacked PRDX1. These results suggest a new treatment approach: lowering PRDX1 levels to make cancer cells more sensitive to DNA-damaging platinum therapies already in use. This highlights PRDX1 not only as a protector of cell function but also as a potential weak point in cancer cells. “As such, we propose that small molecule inhibitors of PRDX1, or single nucleotide polymorphisms that compromise PRDX1 function, in combination with low doses of arsenite can be exploited to treat chemo-resistant tumours.” These findings open the door for the use of PRDX1 as a biomarker to predict treatment response and as a promising target for new combination therapies. For patients with ovarian cancer and potentially other tumors, adjusting PRDX1 levels may help overcome drug resistance and improve outcomes. DOI - https://doi.org/10.18632/oncotarget.28720 Correspondence to: Dindial Ramotar - dramotar@hbku.edu.qa Video short - https://www.youtube.com/watch?v=suOhF7mPlNQ Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28720 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, redox signaling, homologous recombination, protein interaction, cell cycle, protein modification To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

In this deeply personal episode, Mark Chesnut returns to Grief Out Loud to share his experience of losing his sister Glynn to ovarian cancer. Glynn chose medical aid in dying after nearly four years of treatment, giving Mark and his family the unusual experience of knowing when death would occur. This conversation explores the complexity of "scheduled death," the challenges of finding appropriate language to discuss medical aid in dying, and how knowing the date changed their family's grieving process. Mark Chesnut is a journalist, editor, public speaker, and the author of: Prepare for Departure.  Mark previously appeared on Grief Out Loud in October 2022, discussing caring for his mother at the end of her life. Mark lives in New York City with his husband Angel and recently wrote an article about his sister's experience with medical aid in dying.  This episode is the second in our 2025 three-part series highlighting the voices of communities who have historically been underrepresented in the grief world. The series is part of an ongoing collaboration between Dougy Center and The New York Life Foundation. We are deeply grateful for New York Life Foundation's tireless support and advocacy for children and teens who are grieving. Grief Out Loud is a production of Dougy Center, the National Grief Center for Children and Families in Portland, Oregon.

Ahead of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with a variety of oncology experts about the late-breaking abstracts, plenary sessions, and other key presentations that may shift the paradigm across different cancer care fields. They highlighted anticipated clinical trial results that may transform the standard of care for gynecologic malignancies, lung cancer, and other disease types. Rachel N. Grisham, MD, section head of Ovarian Cancer and director of Gynecologic Medical Oncology at MSK Westchester of Memorial Sloan Kettering Cancer Center, shared her anticipation of findings from the phase 3 ROSELLA trial (NCT05257408) assessing relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer. She stated she was excited to see if the data may represent a new opportunity for this patient population. Next, MinhTri Nguyen, MD, a medical oncologist and hematologist at Stanford Health Care, highlighted a few breast cancer presentations to look out for. These topics included a plenary session on data from the phase 3 SERENA-6 study (NCT04964934) evaluating camizestrant in combination with CDK4/6 inhibitors for those with hormone receptor–positive, HER2-negative advanced breast cancer harboring emergent ESR1 mutations. Additionally, Eric K. Singhi, MD, assistant professor in the Department of General Oncology in the Division of Cancer Medicine, and assistant professor in the Department of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center, spoke about a range of potentially practice-changing results in the lung cancer field. For example, he described a session focused on primary results of the phase 3 IMforte trial (NCT05091567) assessing lurbinectedin (Zepzelca) plus atezolizumab (Tecentriq) for those with extensive-stage small cell lung cancer (ES-SCLC). According to Singhi, data from IMforte may shift the paradigm of maintenance therapy for this SCLC population. In the world of head and neck cancer, Douglas R. Adkins, MD, associate professor of Internal Medicine, Division of Oncology, Section of Medical Oncology at Washington University School of Medicine in St. Louis, Missouri, highlighted the session on the phase 3 NIVOPOSTOP GORTEC 2018-01 trial (NCT03576417). Investigators of this study evaluated nivolumab (Opdivo) in combination with chemoradiotherapy for those with resected head and neck squamous cell carcinoma. Adkins noted his excitement to see how these data may impact the standard of care, particularly for patients in Europe, where investigators conducted the study. As part of an Oncology Decoded discussion, Benjamin Garmezy, MD, the associate director of genitourinary research and executive cochair of the Genitourinary Cancer Research Executive Committee at Sarah Cannon Research Institute (SCRI) and medical oncologist at SCRI Oncology Partners specializing in genitourinary cancers, discussed key abstracts in bladder cancer. One specific presentation included additional findings from the phase 3 NIAGARA trial (NCT03732677), which may show how circulating tumor DNA can influence treatment decision-making regarding perioperative durvalumab (Imfinzi) for patients with muscle-invasive bladder cancer.

I'm thrilled to sit down with Dr. Lorna Rodriguez, a medical doctor with a PhD in biochemistry and a true double doc!

Biopharmas developing therapies for obesity are looking to a future where the quality of weight loss matters as much as the quantity — what targets and programs could help realize that vision? On the latest BioCentury This Week podcast, BioCentury's editors discuss the signaling pathways that may exclusively target fat mass while preserving, or even increasing, lean mass — and which companies are playing in the space.The editors also assess what Vinay Prasad's past comments say about how he might lead FDA's Center for Biologics Evaluation and Research (CBER) — and examine how investors are evaluating the possibility that he might move the bar for regulatory approvals. The team then introduces the first in a new BioCentury series, with a look at a Literature Dive into ovarian cancer “atlases” — large-scale molecular profiling studies that point to predictive signatures and patient stratification strategies. This episode was sponsored by Jeito Capital.View full story: https://www.biocentury.com/article/655898#biotech #biopharma #pharma #obesity #FDA #CBER #LifeScience #OvarianCancer00:01 - Sponsor Message: Jeito Capital03:22 - Obesity: Quality over Quantity15:47 - Prasad at FDA27:58 - Ovarian Cancer AtlasesTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

What happens when the doctor becomes the patient?

Featuring perspectives from Dr David M O'Malley and Dr Brian M Slomovitz, including the following topics: Ovarian Cancer; HER2-Directed Therapy for Advanced Gynecologic Cancers — Dr O'Malley (0:00) Endometrial Cancer and Cervical Cancer — Dr Slomovitz (23:38) CME information and select publications

Trigger Warning for todays episode as we are discussing cancer diagnosis, treatments, and the potential impact of these experiences on individuals and families. After today's episode, head on over to @therapybookspodcast to learn about our latest giveaway. *Information shared on this podcast is for information and eductional purposes only. In this weeks episode, Jessica Fowler speaks with Lori Elliot Sacks about her book Unlucky Lori: A Raw and Unfiltered Look at One Woman's Battle with Ovarian Cancer and How HOPE Wins.  In this book, Lori shares her journal of over almost a decade about her experience of going through treatment for Ovarian Cancer and then also being diagnosed with Parkinson's Disease. In this episode, listen is as Lori shares about the difficult times and how she has coped to continue to live a life she wants. She shares examples of ways she could take control in times that it could be difficult.  Lori shares her excitement for life and love of her family, while managing her own struggles through her illness.  Take a listen as Lori shares the insights that have helped her along the way.  About the author: Lori Elliot Sacks: Trouble free and flying high- was Lucky Lori!  I have been a Hospice Nurse, a Therapist, and a Psychiatric Nurse Practitioner. However, the role of patient and ovarian warrior continues to challenge me daily . It demands patience and positivity. This memoir is intense-BEWARE.. but full of HOPE and GRATITUDE.    

In this episode of Bench to Bedside, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, sits down with Dr. Rebecca Whelan, an associate professor of chemistry at the University of Kansas and member of KU Cancer Center's Cancer Biology research program. The discussion focuses on the limitations of the CA125 blood test for ovarian cancer detection and Dr. Whelan's groundbreaking research, which reveals new insights into the structure of the CA125 protein. Dr. Whelan explains how new DNA sequencing technologies and artificial intelligence, specifically the Alpha Fold program, have helped her team improve the understanding and detection of ovarian cancer. Additionally, Dr. Whelan talks about collaborative efforts to identify new biomarkers for early diagnosis of ovarian cancer and shares advice for young scientists interested in making a difference in medicine through chemistry. Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center. Links from this Episode: Learn more about Dr. Whelan's research into CA125 Learn more about ovarian cancer  Read about ovarian cancer screening and diagnosis at KU Cancer Center Learn more about Dr. Rebecca Whelan

Download Your Free Webinar & Ultimate Guide to Water Fasting to Heal Cancer and Chronic Illness https://www.katiedeming.com/prolonged-water-fasting/How would your life transform during a 30-day water fast?Dr. Katie Deming is joined by her client Donna DiPane and medical oncologist Dr. Jason Konner from Memorial Sloan Kettering Cancer Center to share an extraordinary healing journey. Donna recently completed a 30-day supervised water-only fast as part of her holistic approach to healing from ovarian cancer. What makes this story especially powerful is the collaborative relationship between conventional and holistic medicine.Chapters:00:17:00 – The fear wasn't just about cancer00:22:00 – I unzipped from my body00:31:00 – A message from God at 3 am00:38:00 – When the shell started to crack00:52:00 – Strip it all down to healThey explore how fasting goes far beyond physical detoxification. Donna shares the profound spiritual awakening she experienced, including receiving powerful messages during the night, connecting with her "light body," and finding a deep release from the fear that had dominated much of her life. Dr. Konner offers his perspective as a conventional oncologist, describing his initial concerns about safety and his surprise at witnessing Donna's transformation throughout the process - not just physically, but emotionally and spiritually.Listen and learn about what happens during a fast, from the physical challenges of the first week to the emotional and spiritual openings that can occur as the body and mind clear.Disclaimer: Never attempt prolonged fasting without proper medical oversight as it can be dangerous. Send us a text with your question (include your phone number)Join Dr. Katie at CANCER: FROM FEAR TO HOPE on May 8, 2025https://heal.regfox.com/heal-from-fear-to-hopeCode: KATIERESILIENCE10 Transform your hydration with the system that delivers filtered, mineralized, and structured water all in one. Spring Aqua System: https://springaqua.info/drkatie MORE FROM KATIE DEMING M.D. Download Your Free Webinar & Ultimate Guide to Water Fasting to Heal Cancer and Chronic Illness https://www.katiedeming.com/prolonged-water-fasting/6 Pillars of Healing Cancer Workshop Series - Click Here to EnrollWork with Dr. Katie: www.katiedeming.comFollow Dr. Katie Deming on Instagram: https://www.instagram.com/katiedemingmd/ Take a Deeper Dive into Your Healing Journey: Dr. Katie Deming's Linkedin Here Please Support the Show Share this episode with a friend or family member Give a Review on Spotify Give a Review on Apple Podcast DISCLAIMER:The Born to Heal Podcast is intended for informational purposes only and is not a substitute for seeking professional medical advice, diagnosis, or treatment. Individual medical histories are unique; therefore, this episode should not be used to diagnose...

In this episode of From First Period to Last Period, Sarah bravely recounts her ectopic pregnancy — a harrowing experience that included a ruptured fallopian tube and uterus — and how it ultimately inspired her to pursue a career in nursing. Kristyn and ⁠Dr. Jenna Kahn⁠ answer some of your most pressing fertility questions: I'm in my late 30s — how can I improve my egg quality for IVF or natural conception? And what's the real deal with fertility supplements — are they worth it, or just wishful thinking?In breakthrough news, we discuss a promising new blood test for early detection of ovarian cancer — a disease that's often caught too late. Could this innovation change the game for survival rates?Plus, a quick but essential guide to cancer screenings: how to recognize early signs of ovarian cancer, when to get a mammogram, and the latest pap smear guidelines you should know.Hit play now on ⁠Spotify⁠, ⁠Apple Podcasts⁠, ⁠YouTube⁠, or wherever you listen!

What does it mean to survive a diagnosis, and live with cancer? For this episode, we return to the subject that launched the very first season of Overlooked: ovarian cancer, with Teresa Arthur - aka Golda's Mom. Teresa was diagnosed in 2018 and has been living with recurring ovarian cancer for the last seven years, spending almost half of every year in chemotherapy treatment. She talks candidly with Golda about her health challenges and quality of life in survivorship. Take a listen to Teresa's story with ovarian cancer, which we told in our very first season here: https://overlooked.simplecast.com/episodes/fluid-puppySubscribe to the newsletter for more background on this episode: https://overlookedpodcast.kit.com/e4b85028b6If you're in New York City, come to our first listener ‘Meet & Greet' at 787 Coffee in Manhattan on May 31st. Tickets are free but limited - register here.  https://www.eventbrite.ca/e/overlooked-podcast-meet-greet-tickets-1352683656229?aff=oddtdtcreator LIKE WHAT YOU HEAR? Support the show by:- Leaving a review on Apple, Spotify, or wherever you're listening.- Becoming a Patron - Overlooked is on Patreon, where you can and get rewards like merch, the ability to send in questions for expert guests, and a 'backstage pass' to the show. New to Overlooked? Welcome. Overlooked was launched in 2023 to tell the story of ovarian cancer through one woman's story. In 2024 the show started to cover other overlooked topics in women's health - and there are many. The show is hosted by Golda Arthur, an audio journalist and producer. EMAIL US: hello@overlookedpod.com FOLLOW US:Instagram https://www.instagram.com/overlookedpod/LinkedIn https://www.linkedin.com/company/105541285/admin/dashboard/ LEARN MORE: https://overlookedpod.com/ DISCLAIMER What you hear and read on ‘Overlooked' is for general information purposes only and represents the opinions of the host and guests. The content on the podcast and website should not be taken as medical advice. Every person's body is unique, so please consult your healthcare professional for any medical questions that may arise.

Featuring perspectives from Ms Courtney Arn, Ms Jennifer Filipi, Dr David M O'Malley and Dr Shannon N Westin, including the following topics: Introduction: Overview of Ovarian Cancer (OC) Management (0:00) Genetic Testing for Newly Diagnosed Advanced OC (14:31) Role of PARP Inhibitor Maintenance in Newly Diagnosed Advanced OC (22:46) Other Available and Investigational Novel Strategies for OC (43:56) Current and Future Role of Mirvetuximab Soravtansine in OC Treatment (1:19:24) NCPD information and select publications

Plus! Chrissie's back with more sweeping statements and Julia Busuttil joins us for a chat about Witchery's Ovarian Cancer campaign.See omnystudio.com/listener for privacy information.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UYH865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 14, 2026.A New Era in Treating Advanced Ovarian Cancer: Practical Tips for Maximizing the Use of PARP Inhibitors, Immunotherapy, and ADCs In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Merck & Co., Inc., Rahway, NJ, USA, and Sutro Biopharma, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UYH865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 14, 2026.A New Era in Treating Advanced Ovarian Cancer: Practical Tips for Maximizing the Use of PARP Inhibitors, Immunotherapy, and ADCs In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Merck & Co., Inc., Rahway, NJ, USA, and Sutro Biopharma, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UYH865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 14, 2026.A New Era in Treating Advanced Ovarian Cancer: Practical Tips for Maximizing the Use of PARP Inhibitors, Immunotherapy, and ADCs In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Merck & Co., Inc., Rahway, NJ, USA, and Sutro Biopharma, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UYH865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 14, 2026.A New Era in Treating Advanced Ovarian Cancer: Practical Tips for Maximizing the Use of PARP Inhibitors, Immunotherapy, and ADCs In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Merck & Co., Inc., Rahway, NJ, USA, and Sutro Biopharma, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UYH865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 14, 2026.A New Era in Treating Advanced Ovarian Cancer: Practical Tips for Maximizing the Use of PARP Inhibitors, Immunotherapy, and ADCs In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Merck & Co., Inc., Rahway, NJ, USA, and Sutro Biopharma, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UYH865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 14, 2026.A New Era in Treating Advanced Ovarian Cancer: Practical Tips for Maximizing the Use of PARP Inhibitors, Immunotherapy, and ADCs In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Merck & Co., Inc., Rahway, NJ, USA, and Sutro Biopharma, Inc.Disclosure information is available at the beginning of the video presentation.

In this episode, our guest Sharon, from Scotland, shares her powerful journey of overcoming stage 3 ovarian cancer. After a difficult experience with chemotherapy, Sharon turned to cannabis oil—and believes it played a key role in her survival. Now cancer-free and devoted to helping others, she opens up about the stigma, the scams, the healing, and the deeper personal transformation that followed.This is a story of fierce determination, intuitive self-advocacy, and the healing potential of plant medicine.00:38 – Introduction: Ovarian cancer stats and global impact01:52 – Sharon's first symptoms and long path to diagnosis03:02 – The moment she was told she had cancer04:46 – Mental health, grief, and personal transformation06:56 – Relationships lost and reshaped after diagnosis07:10 – Chemotherapy: side effects and regret08:39 – Finding cannabis oil and getting scammed10:29 – The importance of trusted sources and education11:12 – Taking oil before, during, and after chemo13:40 – “I'd be dead without it”—how cannabis helped her survive17:39 – Continued use of oil and current regimen19:31 – Managing chemo-induced neuropathy21:40 – Family dynamics and their view of cannabis23:12 – Survivor's guilt and a desire to help others28:01 – Nutrition, self-care, and guiding others toward options30:57 – Her advice to women newly diagnosed with ovarian cancer34:39 – Final thoughts and gratitude Visit our website: CannabisHealthRadio.comDiscover products and get expert advice from Swan ApothecaryFollow us on Facebook.Follow us on Instagram.Find us on Rumble.Keep your privacy! Buy NixT420 Odor Remover

Diana N. Ionescu, MD - To Target We Need to Test: Why and How to Identify Folate Receptor Alpha-Positive Ovarian Cancer

Diana N. Ionescu, MD - To Target We Need to Test: Why and How to Identify Folate Receptor Alpha-Positive Ovarian Cancer

Featuring perspectives from Dr Kathleen N Moore, Dr Ritu Salani, Dr Angeles Alvarez Secord and Dr Shannon N Westin, moderated by Dr Secord, including the following topics: Introduction (0:00) Up-Front Treatment for Advanced Ovarian Cancer (OC) — Dr Westin (2:42) Management of Relapsed/Refractory OC — Dr Secord (23:06) Novel Investigational Therapies for Advanced OC — Dr Moore (46:55) Diagnosis and Management of Adverse Events Associated with Commonly Employed Therapies for Advanced OC — Dr Salani (1:08:34) CME information and select publications

Dr Kathleen Moore, Dr Ritu Salani, Dr Shannon Westin and moderator Dr Angeles Alvarez Secord share their perspectives and summarize recently presented data from the SGO 2025 annual meeting guiding the management of ovarian cancer. CME information and select publications here.

Each year, thousands of people come together to participate in the Support Connection's Annual Support-A-Walk for Breast & Ovarian Cancer, an uplifting community event dedicated to raising awareness and providing support for those living with breast, ovarian, or any gynecological cancer. Family members, friends, and supporters unite to celebrate, encourage, and remember their loved ones affected by these cancers. It's a powerful reminder that no one should face cancer alone, and the event serves as an opportunity for individuals, businesses, and organizations to express their compassion and support for those going through their cancer journeys. On October 6, 2024, Westchester Talk Radio's Andrew Castellano had the opportunity to speak with Violeta, a participant at the event.

The Support Connection's Annual Support-A-Walk for Breast & Ovarian Cancer held on October 6, 2024, was a powerful and inspiring community event that brought together thousands of participants united by a shared mission: to support individuals living with breast, ovarian, or any gynecological cancer. Held each year, the Support-A-Walk raises essential funds to provide free support services such as one-on-one peer counseling, support groups, educational and wellness programs, and social activities. These services have made a profound difference in the lives of those facing cancer, offering them hope, strength, and a sense of community. The event is not only about raising funds—it's about creating a space where people can feel supported and connected. Families and friends walked together, celebrating survivors, supporting those currently battling cancer, and remembering those who have been lost. The walk serves as a reminder that no one has to face cancer alone. Businesses, organizations, and individuals from the community came together, showing their encouragement and compassion through participation, sponsorship, and donations. During the event, Westchester Talk Radio's Andrew Castellano had the opportunity to speak with Stacey Thompson about the meaningful impact of Support Connection's work.

To have your question featured in a future video, please email: questions@morses.tv Please include at least: Age, Weight and as much history as possible.

In 2014, at the age of 51, Diane was diagnosed with stage 4 ovarian cancer with a BRCA mutation. Doctors told her she had just months to live. In this episode, Diane Doyle shares how she took control of her own healing, the challenges she faced in navigating both conventional and alternative treatments, and why she believes cannabis was the key to her survival. Her story is a testament to the power of perseverance, self-education, and never giving up hope.01:13 – Diane's initial diagnosis and how it was discovered04:35 – Reaction to being told she had only months to live06:58 – How Diane approached her healing journey from the beginning10:42 – Why she chose to combine conventional and alternative treatments14:25 – Discovering cannabis and how she began using it18:09 – The reaction from her doctors20:55 – What Diane believes made the biggest difference in her outcome24:36 – Side effects, setbacks, and how she adjusted29:45 – The emotional and spiritual aspects of healing33:10 – Where she is today, 11 years later36:22 – Advice for others facing a similar diagnosis39:00 – Final thoughts and gratitude Visit our website: CannabisHealthRadio.comFollow us on Facebook.Follow us on Instagram.Find us on Rumble.Keep your privacy! Buy NixT420 Odor Remover

About this episode: For some people with a high risk of ovarian cancer, a standard approach has been full removal of the reproductive organs. But new research points to a far less invasive procedure called a salpingectomy, or removal of the fallopian tubes, as a potential “game changer” in ovarian cancer. In this episode: understanding high grade serous carcinoma—the most common type of ovarian cancer—the lack of screening tools, and why fallopian tube removal isn't yet available to more people. Guest: Dr. Rebecca Stone is an OBGYN, a professor in the Johns Hopkins Medicine Department of Gynecology and Obstetrics, and the director of The Kelly Gynecologic Oncology Service. Host: Stephanie Desmon, MA, is a former journalist, author, and the director of public relations and communications for the Johns Hopkins Center for Communication Programs, the largest center at the Johns Hopkins Bloomberg School of Public Health. Show links and related content: A Game-Changer for Ovarian Cancer—Johns Hopkins Medicine Salpingectomy for ectopic pregnancy reduces ovarian cancer risk—JNCI Cancer Spectrum Salpingectomy for the Primary Prevention of Ovarian Cancer: A Systematic Review—NIH Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed

In 2017 Sharon was diagnosed with ovarian cancer. She underwent a radical surgery and chemotherapy. She had a recurrence in late 2019 and after more chemotherapy was told she had widespread bone metastacies. At that point, Sharon stopped all conventional treatment and opted for mistletoe and a functional medicine approach. She has been NED since late 2020 and continues with functional medicine and mistletoe. Today Sharon lives in London, is a clinical nurse and a trained functional medicine practitioner. She is passionate about raising awareness around ovarian cancer and functional medicine.  To learn more about Sharon and her healing journey visit - sharondobbs-richards.com or email her directly at sharon@sharondobbs-richards.com. You can purchase Sharon's novel called, How To Kill Your Gynecologist, on Amazon Follow Sharon on LinkedIn  To find your Functional Medicine practitioner visit www.ifm.org Learn more about Sharon's breathwork practitioner at sophietrew.com ________________ To learn more about the 10 Radical Remission Healing Factors, connect with a certified RR coach or join a virtual or in-person workshop visit www.radicalremission.com. To watch Episode 1 of the Radical Remission Docuseries for free, visit our YouTube channel here.  To purchase the full 10-episode Radical Remission Docuseries visit Hay House Online Learning. To learn more about Radical Remission health coaching with Liz or Karla, Click Here Follow us on Social Media: Facebook  Instagram YouTube ______________ Thank you to our friends from The Healing Oasis for sponsoring this episode of the podcast.  The Healing Oasis is a first of its kind in beautiful British Columbia, Canada where we encourage the body to heal from cancer using alternative therapies & cancer fighting meals at a wellness retreat center in nature. Our top naturopathic cancer doctor will prescribe a protocol tailored specifically for you. There's no place quite like it. Start your healing journey today! Learn More about The Healing Oasis by visiting these links: Website   Testimonials Video Overview  

This special Encore Episode of the SolFul Connections podcast features Taylor O' Brien, who shares how her diagnosis farian Cancer in her twenties has shaped her perspective on healthcare, wellness, and life.Armed with knowledge and a mission, Taylor reveals some important insights and advice that could help all of us navigate our own wellness journey. The conversation with this young, beautiful, and brave woman is inspiring and thought-provoking. Friendship, advocacy, and who we are at our core are all topics addressed in this special discussion.For more on Cancer - and the low-grade Ovarian Cancer with which Taylor was diagnosed, visit www.cancer.orgHelp me to honor and applaud Taylor, who continues to spread her message and her powerful light.

In the first episode of A Deep Dive into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we're speaking with Dr. Kathleen Moore about HRD testing in ovarian cancer and its clinical significance in helping aid precision medicine approaches.   Dr. Kathleen Moore is a Professor of Gynecologic Oncology at the University of Oklahoma Health Sciences Center, Associate Director of Clinical Research and Director of the Oklahoma TSET Phase I Program at the Stephenson Cancer Center. A graduate of the University of Washington School of Medicine, WA, Dr. Moore completed her residency in gynecology at the University Health Center of Pittsburgh in Pittsburgh, PA and completed a fellowship in gynecologic oncology at the University of Oklahoma College of Medicine in Oklahoma City, OK. She is board certified in obstetrics and gynecology as well as gynecologic oncology and hospice and palliative care.   For more information, visit: https://www.azprecisionmed.com/tumor-type/ovarian-cancer/hrd-testing.html For patient resources, please visit TestForHRD.com.   This podcast does not necessarily reflect the opinions of AstraZeneca and are the spokeperson's opinions and experience.

In the third episode of A Deep Dive Into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we're speaking with Dr. David O'Malley, and Bobbie R, an ovarian cancer patient. Dr. O'Malley will highlight how HRD testing empowers ovarian cancer patients to make more informed decisions with their doctors to help guide their treatment journey, and Bobbie will provide insight into her experience with HRD testing.   Dr. David O'Malley is a professor in the department of Obstetrics and Gynecology at The Ohio State University College of Medicine and the director of the Division of Gynecologic Oncology at the OSUCCC – James.   Bobbie is a stage 3C ovarian cancer patient who lives in Rochester, New York. Bobbie is an animal rights activist, vegetarian, and exerciser who recently retired from the healthcare field, having worked as a registered nurse and owner of a healthcare staffing firm. Following her diagnosis in July of 2021, Bobbie participated in biomarker testing which indicated that she was breast cancer gene (BRCA) negative and homologous recombination deficiency (HRD) positive. After undergoing surgery and chemotherapy as first-line treatment, Bobbie's oncologist explained that she was eligible for a poly-ADP ribose polymerase (PARP) inhibitor due to her HRD status and on March 7, 2022, Bobbie started on a PARP inhibitor for maintenance treatment. As she continues treatment in 2024, Bobbie celebrates over 45 years of marriage with her husband and looks forward to traveling the United States, reading good books, and spending time with her dogs.   For more information, visit https://www.azprecisionmed.com/tumor-type/ovarian-cancer/hrd-testing.html   For patient resources, please visit TestForHRD.com.   This podcast does not necessarily reflect the opinions of AstraZeneca and are the spokespeople's opinions and experiences.